Warner Carr, MD, principal investigator in the clinical development of the drug, said in a Meda Pharmaceutical press release that “Dymista has ... “this new nasal spray combination of 2 ...

The dispute pertains to patents covering Meda’s Dymista nasal spray, used to treat seasonal allergic rhinitis. Cipla supplies some of the drug ingredients to Meda, besides marketing it in some ...

* Perrigo Company Plc - ‍settled hatch-waxman litigation relating to dymista nasal spray brought by MEDA Pharmaceuticals Inc and Cipla Ltd Source text for Eikon: Further company coverage: ...

In a BSE filing, Cipla said “they sued Apotex Inc and Apotex Corp in Federal District Court in Delaware to enforce the Orange—Book listed patents covering ‘Dymista’ Nasal Spray.” ...